Impact of varicella vaccine on nosocomial outbreaks and management of post exposure prophylaxis following in a paediatric hospital

• Published in: PloS one Vol. 16; no. 5; p. e0251496
• Main Authors: Gentile, Angela, Giglio, Norberto, Lucion, Maria Florencia, Martínez, Ana Clara, Pejito, Natalia, Juarez, Maria Del Valle
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 20.05.2021; Public Library of Science (PLoS)
• Subjects: Biology and life sciences; Chicken pox; Children; Cost control; Costs; Discharge; Disease prevention; Diseases; Economic impact; Epidemics; Epidemiology; Evaluation; Hospitals; Immunization; Impact analysis; Medicine and Health Sciences; Nosocomial infection; Outbreaks; Patients; Pediatrics; People and Places; Prevention; Prophylaxis; Seasonal variations; Social Sciences; Surveillance; Vaccines; Varicella; Varicella-zoster virus; Argentina
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0251496

In 2015, varicella vaccine was introduced to the National Immunization Programme in a one-dose regimen for infants aged 15 months. The aim of this study was to describe and compare the epidemiologic characteristics, management strategies and costs of varicella outbreaks in Ricardo Gutierrez Children's Hospital (HNRG) from 2000 to 2019, before (PreV period) and after (PostV period) the introduction of the varicella vaccine. A retrospective, analytic study of the impact of nosocomial varicella outbreaks at the HNRG, based on active epidemiologic surveillance. We compared nosocomial varicella outbreaks rates (per 10,000 discharges) between PreV and PostV, excluding the intervention year (2015). During PreV, an average of 15.87 (13.91-18.02) outbreaks per year was observed and in PostV 5.5 per year (3.44-8.32). Outbreaks adjusted by all cause discharges showed a reduction of 59.13% (-36.68%, -73.62%) after vaccine introduction. Considering that in PreV the average of susceptible cases per outbreak was 5.0 and in PostV 7.8, with a cost per susceptible of AR$ $6,522 (80.27 USD) PreV and 6,708 PostV the economic impact on the reduction of outbreaks after the introduction of the vaccine, showed an estimated average savings per year of AR$ -252,128 AR$ (-3,103.11 USD). The number of annual varicella hospital outbreaks at the HNRG decreased significantly after varicella vaccine was introduced to NIP in Argentina with a relevant reduction in terms of costs.